Evidence map›Paper›PMID 41871528›Full record

ArticleJournal of diabetes science and technology2026

Real-World Follow-Up of People With Type 2 Diabetes Using a Mobile Diabetes App With Connected Glucose Meters Finds Improvements in Glycemia Are Durable Over 5 Years.

Mike Grady, Stephen MacKintosh, Matthew Fryett, Stuart Phillips, Elizabeth Holt

Abstract read
In one paragraph

Article in Journal of diabetes science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mike GradyLifeScan Scotland Ltd, Inverness, UK.ORCID 0000-0002-8006-1844
Stephen MacKintoshLifeScan Scotland Ltd, Inverness, UK.
Matthew FryettLifeScan Scotland Ltd, Inverness, UK.
Stuart PhillipsLifeScan Scotland Ltd, Inverness, UK.ORCID 0000-0003-2399-9016
Elizabeth HoltLifeScan Global Corporation, Malvern, PA, USA.ORCID 0000-0003-4329-3379

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEvidence from long-term, real-world use of blood glucose (BG) monitoring technologies is sparse. We investigated whether using a diabetes app with connected meters could support durable diabetes management improvements in people with type 2 diabetes (T2D) over 5-years.

methodsAnonymized glucose and app analytics from 501 people with T2D were extracted from our server. The first 14 days using the app were compared with the last 14 days of each consecutive year for 5 years, using paired within-subject differences. Subjects had ≥365 BG readings per year.

resultsPeople with T2D improved BG readings in range (RIR, 70-180 mg/dL) by +6.9 percentage points (%pts, 74.6% to 81.5%) and readings in tight range (RITR, 70-140 mg/dL) by +7.8%pts (49.2% to 57.0%) at year 1. Year 1 improvements in RIR and RITR remained evident at year 5 (+7.5%pts and +7.7%pts, respectively). Reductions in hyperglycemic readings (>180 and >250 mg/dL) explained the improvements in RIR and RITR over the 5-years. Mean BG reduced by -9.1 mg/dL at year 1 (150.2 to 141.1 mg/dL) and this was sustained at year 5 (-10.6 mg/dL, 150.2 to 139.6 mg/dL). Subjects performed BG checks at a consistent level, equivalent to 1.8 to 2.1 checks per day, over 5 years. All these glycemic changes were significant (p<0.001). Higher app engagement (>4 app sessions per week) effected better diabetes management.

conclusionReal-world follow-up of people with type 2 diabetes using a diabetes app with connected meters found improvements in glycemia were durable over 5-years.

Indexed as

blood glucose monitoringdiabetes appreal-world evidence

Identifiers

PMID41871528
PMCPMC13008783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.